Etiome

News

Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.